# Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates

> **NCT04816461** · PHASE4 · COMPLETED · sponsor: **Institut de Recherche en Sciences de la Sante, Burkina Faso** · enrollment: 526 (actual)

## Conditions studied

- Malaria
- Malaria Prophylaxis
- Mass Testing and Treatment

## Interventions

- **DRUG:** Amodiaquine Sulfadoxine-Pyrimethamin administration
- **DRUG:** Dihydroartemisinin-Piperaquine
- **DIAGNOSTIC_TEST:** Standard HRP2-RDT

## Key facts

- **NCT ID:** NCT04816461
- **Lead sponsor:** Institut de Recherche en Sciences de la Sante, Burkina Faso
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-07
- **Primary completion:** 2023-06-30
- **Final completion:** 2023-06-30
- **Target enrollment:** 526 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04816461

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04816461, "Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04816461. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*